σ-1 selective ligand which binds with high affinity to human malignant melanoma cells A 2058.
Desiccate at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Max Conc. mg/mL
Max Conc. mM
Preparing Stock Solutions
The following data is based on the product molecular weight 358.22.
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect
the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass
Calculate the mass, volume, or concentration required for a solution.
Calculate the dilution required to prepare a stock solution.
References are publications that support the biological activity of the product.
[125I]N-(2-Piperidinylaminoethyl)-4-iodobenzamide and related analogues as sigma receptor imaging agents; high affinity binding to human malignant melanoma and rat C6 glioma cell lines.
Currently there are no citations for N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide.
Which Brands are Currently Available on bio-techne.com? R&D Systems and Tocris Bioscience products are available to purchase through bio-techne.com. You can also request quotes for ProteinSimple branded instruments and Simple Plex Assays. ProteinSimple branded instrument consumables and ACD branded products will be available on bio-techne.com in the near future. Novus Biologicals branded products are not currently available on bio-techne.com and can be found at novusbio.com.
Setting the standard in quality research reagents for over 30 years
A trusted leader in quality life science reagents
Your trusted supplier for innovative and high performance life science reagents
Proprietary systems and consumables for simpler, more quantitative and affordable protein analysis
Proprietary RNAscope® technology capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity
A world leader in developing liquid biopsy based diagnostics